Early convalescent plasma treatment may lower long COVID risk, study finds

Plasma from recovered patients, helpful in preventing severe COVID, could also decrease likelihood of post-COVID symptoms

Related Keywords

Maryland ,United States ,Johns Hopkins University ,American ,Barbara Benham ,Michael Newman ,Aaron Tobian ,David Sullivan ,Kelly Gebo ,Translational Sciences ,Moriah Fund ,Transfusion Medicine Division ,Healthnetwork Foundation ,Defense Health Agency ,National Institute Of Allergy ,Nuclear Defense ,Division Of Intramural Research ,Twitter ,Johns Hopkins University School Of Medicine ,American Society For Microbiology ,Bloomberg School ,Johns Hopkins Bloomberg School Of Public Health ,National Center ,School Of Medicine ,Mental Wellness Foundation ,Shear Family Foundation ,Johns Hopkins Medicine ,Johns Hopkins Bloomberg School ,Public Health ,American Society ,Johns Hopkins University School ,Joint Program Executive Office ,Bloomberg Philanthropies ,National Institute ,Infectious Diseases ,Intramural Research ,Advancing Translational Sciences ,Octapharma Plasma ,Shear Family ,